BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19
Westport, CT, April 03, 2020 (GLOBE NEWSWIRE) --
- Introduction to ViralClear management and scientific team
- Strategy for rapid FDA advancement of Vicromax(tm)
- Update on BioSig core business developments and commercialization plans
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced that it intends to provide a public business update via teleconference regarding its recently acquired anti-viral pharmaceutical candidate, Vicromax(tm). The briefing is being held on Tuesday, April 7, 2020 at 11am ET.
ViralClear Pharmaceuticals, Inc. will be represented by Nick Spring, CEO, Steven King, COO and Jerome Zeldis, M.D., Ph.D, Executive Chair. BioSig will be represented by Kenneth L. Londoner, MBA, Chairman and CEO of BioSig Technologies, Inc.
Conference Call Details:
Date: Tuesday, April 7, 2020
Time: 11:00 A.M. Eastern Time (ET)
Dial in Number for U.S. Callers: 1- 877-407-8293
Dial in Number for International Callers: 1- 201-689-8349
A replay will be available for two weeks starting on April 7, 2020 at approximately 2:00 P.M. ET. To access the replay, please dial 1- 877-660-6853 in the U.S. and 1- 201-612-7415 for international callers. The conference ID# is 13701652.
In a preliminary internal review, the orally administered, broad-spectrum anti-viral agent Vicromax(tm) demonstrated strong activity against COVID-19 in cell cultures in laboratory testing. In this analysis, Vicromax(tm) was added to a tissue culture assay for SARS-CO-2 coronavirus (the causative agent for COVID-19) and an anti-viral effect was observed, which led to a reduction of over 90% of infectious viruses. The Company intends to pursue development of this agent for the treatment of COVID-19 through FDA-approved clinical trials.
The product candidate already completed Phase I and three Phase II clinical trials involving over 134 subjects for indications other than COVID-19, and underwent extensive animal testing and human clinical experience. The Company expects that Vicromax(tm) might be used alone or in a combination with other anti-viral agents or immune modulators.
About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 firstname.lastname@example.org 203-409-5444, x133
Released April 3, 2020